|IBIS II (DCIS)
||An International Multi-Centre Study of Tamoxifen (anti-oestrogen drug) vs. Anastrozole (inhibits the enzyme responsible for biosynthesis of oestrogens) in postmenopausal women with hormone sensitive Ductal Carcinoma In Situ (DCIS).
|IBIS II (Prevention)
||An International Multi-Centre Study Of Anastrozole (inhibits the enzyme responsible for biosynthesis of oestrogens) Versus Placebo In Postmenopausal Women At Increased Risk Of Breast Cancer.
||A phase III trial evaluating the role of ovarian function suppression and the role of exemestane (inhibitor of the aromatase enzyme) as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
||A phase III trial evaluating the role of exemestane plus GnRH analogue (reduces the levels of testosterone or oestrogen) as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.
||Phase II of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms (PARAGON).
||Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation for breast cancer.
||A randomised phase III trial of exemestane (inhibitor of the aromatase enzyme) vs. anastrozole (inhibits the synthesis of oestrogen) in postmenopausal women with hormone receptor-positive primary breast cancer.
||Randomised trial of letrozole plus usual care versus usual care without letrozole to prevent new breast cancer events in postmenopausal women who have completed a minimum of 4 years of adjuvant endocrine therapy for early, hormone responsive breast cancer more than 1 year previous, and who are disease-free at trial entry.
||Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.
||A randomised comparison of anastrozole (inhibits the synthesis of oestrogen) commenced before and during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (STARS - Study of Anastrozole and Radiotherapy Sequencing).